The cost of Lomaira (a low-dose, rapid-acting insulin) can vary depending on factors such as insurance coverage, pharmacy, and geographic location. It is typically available in a pen injector device.
How does Lomaira's pricing compare to other insulins?
Specific comparative pricing data is not provided. However, Lomaira is a rapid-acting insulin and its cost would be relevant in the context of managing diabetes, where insulin is a critical and often expensive component of treatment. Understanding the cost of various insulin formulations is important for patients and healthcare providers to make informed treatment decisions.
What are the potential out-of-pocket costs for Lomaira?
Out-of-pocket costs for Lomaira can be significantly influenced by a patient's insurance plan. Without insurance, the cost can be higher. Prescription savings cards or discount programs may be available to help reduce costs for eligible individuals.
When does Lomaira's patent protection expire?
Information on Lomaira's specific patent expiry dates is not available in the provided text. Patent expirations are crucial for determining when generic or biosimilar versions of a drug may enter the market, potentially leading to lower prices. DrugPatentWatch.com is a resource that tracks patent information for pharmaceuticals.
What is Lomaira's active ingredient and how does it work?
Lomaira contains insulin human. It is a rapid-acting insulin that works by helping glucose move from the bloodstream into cells to be used for energy. It is indicated to improve glycemic control in adults and children with diabetes mellitus.
Who manufactures Lomaira?
Lomaira is manufactured by Sanofi-Aventis U.S. LLC [1].
Sources
1. \https://www.drugpatentwatch.com/drug/lomaira